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Abstract
Idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD) are
both debilitating lung diseases which can lead to hypoxemia and pulmonary hypertension
(PH). Nuclear Factor of Activated T-cells (NFAT) is a transcription factor implicated in the
etiology of vascular remodeling in hypoxic PH. We have previously shown that mice lacking
the ability to generate Vasoactive Intestinal Peptide (VIP) develop spontaneous PH, pulmonary arterial remodeling and lung inflammation. Inhibition of NFAT attenuated PH in these
mice suggesting a connection between NFAT and VIP. To test the hypotheses that: 1) VIP
inhibits NFAT isoform c3 (NFATc3) activity in pulmonary vascular smooth muscle cells; 2)
lung NFATc3 activation is associated with disease severity in IPF and COPD patients, and
3) VIP and NFATc3 expression correlate in lung tissue from IPF and COPD patients. NFAT
activity was determined in isolated pulmonary arteries from NFAT-luciferase reporter mice.
The % of nuclei with NFAT nuclear accumulation was determined in primary human pulmonary artery smooth muscle cell (PASMC) cultures; in lung airway epithelia and smooth muscle and pulmonary endothelia and smooth muscle from IPF and COPD patients; and in
PASMC from mouse lung sections by fluorescence microscopy. Both NFAT and VIP mRNA
levels were measured in lungs from IPF and COPD patients. Empirical strategies applied to
test hypotheses regarding VIP, NFATc3 expression and activity, and disease type and
severity. This study shows a significant negative correlation between NFAT isoform c3
protein expression levels in PASMC, activity of NFATc3 in pulmonary endothelial cells,
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expression and activity of NFATc3 in bronchial epithelial cells and lung function in IPF
patients, supporting the concept that NFATc3 is activated in the early stages of IPF. We further show that there is a significant positive correlation between NFATc3 mRNA expression
and VIP RNA expression only in lungs from IPF patients. In addition, we found that VIP
inhibits NFAT nuclear translocation in primary human pulmonary artery smooth muscle cells
(PASMC). Early activation of NFATc3 in IPF patients may contribute to disease progression
and the increase in VIP expression could be a protective compensatory mechanism.

Introduction
Pulmonary hypertension (PH) is an important clinical indicator of the severity of both IPF
and COPD [1]. In patients with IPF, idiopathic PH (IPAH), and COPD, pulmonary vascular
remodeling may lead to pulmonary hypertension and cor pulmonale [2].
Nuclear factor of activated T cells (NFAT) belongs to a family of four isoforms of Ca2+/calcineurin-dependent transcription factors which play an important role in immune function
[3]. Besides the importance of this family of transcription factors in immune regulation, the
isoforms NFATc3 and NFATc2 have been particularly implicated in the development of PH
[4–7]. NFATc3 is linked to pulmonary arterial smooth muscle (PASMC) hyperplasia and
hypertrophy in chronic hypoxia-induced PH [4,6,7]. In addition, it has been shown that
NFATc3 represses the expression of voltage-dependent potassium channels (Kv 2.1) [8] and
large conductance potassium channel β subunit [9], upregulates the expression of transient
receptor potential cation channel subtype C1 (TRPC1) [10] and smooth muscle α-actin [6,11],
suggesting it might be implicated in the regulation of vascular smooth muscle contractility.
Furthermore, NFATc2 is implicated in the downregulation of Kv1.5 expression, membrane
depolarization, proliferation and resistance to apoptosis of PASMC in idiopathic PAH patients
and in rats with monocrotaline-induced PH [5,12]. However, little is known about the role of
NFAT in pulmonary vascular endothelium. Recent reports show that vascular endothelial
growth factor (VEGF)-mediated activation of calcineurin/NFAT signaling upregulates angiopoietin-2 in lung endothelial cells [13]. In the systemic circulation, it has been shown that NFAT
activation regulates angiogenesis [14,15]. A delicate balance of angiogenic and angiostatic factors
regulates vessel homeostasis in normal physiologic conditions in the lungs. There is increased
angiogenesis in COPD [16]. However, controversy exists regarding whether angiogenesis is
increased or decreased in IPF [17]. Therefore, NFAT could play different roles depending on the
vascular cell in which it is activated and the underlying clinical disease process.
We have shown previously that Vasoactive Intestinal Peptide (VIP) knockout mice develop
spontaneous pulmonary hypertension and T lymphocytic infiltration of the airways and vasculature [18,19] and that administration of VIVIT peptide (an inhibitor of NFAT) reduces
inflammation and pulmonary arterial remodeling in these mice. In addition, VIP attenuates
monocrotaline-induced pulmonary hypertension in rats [20] in which NFAT has been implicated in disease pathogenesis. These studies then suggest a link between VIP and NFAT. VIP
has been described, with respect to the pulmonary circulation, merely as a vasodilator of pulmonary vessels [21–25] but also suppresses vascular smooth muscle cell proliferation [26].
These actions are mediated primarily by reducing intracellular Ca2+ via activation of the
cAMP/protein kinase A (PKA) pathway [26].
These findings led us to test the following hypotheses:
1) VIP reduces NFATc3 transcriptional activity. 2) Lung NFATc3 activation and VIP
mRNA expression are associated with disease severity in individuals with IPF and COPD.
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Materials and Methods
Animals
All protocols employed in this study were reviewed and approved by the Institutional Animal
Care and Use Committee of the University of New Mexico, School of Medicine (Albuquerque,
NM).
Adult (2–3 month old) male 9x-NFAT-luciferase reporter (NFAT-luc) mice (20–25 g) were
used. NFAT-luc mice were provided by Dr. Jeffery D. Molkentin (Department of Pediatrics,
Children’s Hospital Medical Center, Cincinnati, Ohio) [27]. These mice carry 9 copies of an
NFAT binding site from the IL-4 promoter (50 -TGGAAAATT-30 ) positioned 50 to a minimal
promoter from the α-myosin heavy chain gene (−164 to +16) and inserted upstream of the
luciferase reporter [27]. VIP knockout (KO) mice, backcrossed to C57BL/6 mice, were obtained
from Dr. Colwell, Mental Retardation Res. Ctr., Univ. of California, Los Angeles [28]. All mice
were euthanized by removing the heart and lungs under pentobarbital anesthesia.
Chronic hypoxia exposure. Animals designated for exposure to chronic hypobaric hypoxia (CH) were housed in a hypobaric chamber with barometric pressure maintained at ~380
Torr for 2 days. Control animals were housed at ambient barometric pressure (normoxia, N,
~630 Torr). All animals were maintained on a 12:12-h light-dark cycle.
Animal treatments. Treatment was started one day prior to CH exposure, followed by 2
days during CH. NFAT-luc mice were treated with 0.166 mg/kg/day VIP administered s.c. via
osmotic pumps (Alzet). Control animals received vehicle alone (saline).

Human samples
Studies were authorized by a SUNY Stony Brook and UNM HSC Institutional Review exempt
materials transfer agreement. RNA-later protected and formalin fixed-paraffin embedded lung
tissue, with associated de-identified clinical data from patients with COPD or IPF, were
obtained from the NIH Lung Tissue Research Consortium (LTRC).
Clinical and demographic data (S1 Table) were de-identified and anonymously-coded by
the NIH and divided in the following groups: group 1 (control): smokers with slightly compromised lung function (FEV1 > = 80%), group 2: smokers with mildly compromised lung function (FEV1 is 50–80%); group 3: smokers with severely compromised lung function (FEV1
<50%) and group 4: smokers with IPF (FVC < 50%). Each group consisted of 9–10 patients.

Assays
Luciferase activity. Intrapulmonary arteries were isolated from NFAT-luc mice and lysed
(Promega buffer). Luciferase activity was measured using a Luciferase Assay System kit (Promega, Madison, WI), and light detected with a luminometer (TD20/20, Turner). Protein content was determined by the Bradford method (BioRad, Hercules, CA) and used to normalize
luciferase activity.
Cell culture and NFATc3 nuclear import. Human PASMC (Life Technologies, Carlsbad,
CA) were grown in poly-L-lysine (10 μg/ml) coated flasks in Growth Medium 231 (Life Technologies, Carlsbad, CA) at 37˚C in 5% CO2 with controlled humidity. Cells were electroporated (Nucleofector, Lonza, Basel, Switzerland) with NFATc3-EGFP (enhanced green
fluorescent protein) expression vector. This vector was created by Dr. F. McKeon (Harvard
University, Cambridge, MA) and kindly provided by Dr. L.F. Santana (Washington State University, Seattle, WA). Electroporated cells were seeded on microscope coverslips coated with
poly-L-lysine, cultured in Growth Medium 231 (Life Technologies, Carlsbad, CA) at 37˚C in
5% CO2 with controlled humidity. Before any experiment, cells were cultured for at least 48
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hrs. in differentiation media that contained 1% FBS and 30 μg/ml heparin (Life Technologies,
Carlsbad, CA). In all the experiments, cells were pre-incubated with a myosin light chain
kinase peptide inhibitor (MLCK, 1 μM) to prevent cell contraction and detachment. Then,
cells were subjected to different treatments described in results section. Nuclear EGFP fluorescence was monitored using a NIKON Diaphot 300 at 200X magnification. Individual cells
were imaged once every minute for 30 minutes. Images were captured using Andor IQ 1.9
software (Belfast, UK). Nuclear fluorescence (F) was background corrected and expressed as
fold change from baseline nuclear fluorescence (F/F0) (Metamorph Universal Imaging software, Molecular Devices, Sunnyvale, CA).
NFATc3 immunofluorescence confocal microscopy. Paraffin lung sections from WT
and VIP KO mice were de-paraffinazed, subject to antigen retrieval process, permeabilized,
blocked for nonspecific binding, and primary antibodies [rabbit polyclonal anti-NFATc3;
1:100 (Santa Cruz Biotechnology) and anti-α-actin; 1:250 (Sigma)] were prepared in 0.2% gelatin in PBS and applied overnight at 4˚C. Secondary antibodies [anti-rabbit Cy5 and anti-mouse
Cy3; 1:500 (Jackson ImmunoResearch Laboratories)] were prepared in 0.2% gelatin in PBS and
applied for 1 h at room temperature. Nuclei were stained using SYTOX green (1:5,000 in PBS;
Molecular Probes). Sections were examined using a x63 objective on Leica TCS SP5 laser scanning confocal microscope. Specificity of immune staining was confirmed by the absence of fluorescence in tissues incubated with primary or secondary antibodies alone. For scoring of
NFATc3-positive nuclei, multiple fields for each vessel were imaged and counted by two independent observers blinded to the treatment using MetaMorph software (Universal Imaging) as
previously described [6,29,30]. The software was programmed so that individual pixels would
appear white instead of yellow if the green nucleic acid stain and red NFATc3 stain colocalized.
Thus a cell was considered positive if co-localization (white) was uniformly distributed in the
nucleus and negative if no co-localization (green only) was observed.
Paraffin lung sections from the four patient’s groups were processed and immuno-stained
as described above. NFATc3 integrated intensity (AU) was measured in the threshold individual channels in pulmonary arterial smooth muscle and endothelial cells and in airway smooth
muscle and epithelial cells using Metamorph software. The same threshold was applied to
every image.
Airway and vascular remodeling. Paraffin lung sections from the four patient’s groups were
de-paraffinazed and stained with hematoxylin and eosin for standard morphologic analysis.

Statistical analysis and models
Animal testing. Animal data were expressed as mean ± SEM. Statistical significance was
tested at 95% (p<0.05) confidence level using unpaired t-test or one-way ANOVA followed by
Newman-Keuls multiple comparisons test or Kruskal-Wallis One Way Analysis of Variance
on Ranks if data did not pass the equal variance test.
Human testing. A variety of tests were conducted on the human data to tease out robust
relationships in our hypothesis-testing. Using the data from the human samples across the
four disease groups we perform multivariate analyses of FEV1/FVC% and remodeling outcomes against our key independent variables NFATc3 fluorescence intensity in airway and
pulmonary vascular cells as well as the percent NFATc3 positive nuclei. Other independent
variables of interest included were VIP and NFATc3 mRNA levels. Gender, age, race, and
smoking intensity were the confounding factors included in the analysis.
Measurement of independent variables. Given the small sample sizes in the remodeling
analysis, factor analysis was used to retain only the common factors NFATc3 intensity for airway epithelial and smooth muscle cells and for pulmonary endothelial and smooth muscle
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cells. Factor analysis is a data reductionist methodology that combines multiple indicators of
latent variables in order to capture the commonalities and minimize noise. Two types of factor
analysis were used. Exploratory factor analysis of a correlation matrix in order to capture the
shared variances in the four indicators was used first. The prior was that the two airway cells
could be collapsed into one latent factor and the two pulmonary cells could do the same. The
exploratory factor analysis results confirmed our priors in that the first two eigenvalues
explained most of the variation in the four indicators. The first factor loads predominantly on
the NFATc3 airway intensity scores while the second factors loads onto the pulmonary vascular intensity scores. Confirmatory factor analysis was also run but since the exploratory is less
restrictive and the assumption of two factors did not need to be imposed, the exploratory
results were used. Factor analysis results are reported in Appendix A. These analyses confirmed our hypotheses that the indicators can be matched to two mutually exclusive domains
related to airway and pulmonary vascular NFATc3 staining intensities. These constructed
indices were only used in the remodeling outcomes given smaller samples with less power. For
the models of FEV1/FVC %, the original variables were used.
Our hypothesis is that the effects of the NFATc3 activation vary by disease type and severity.
In other words, the interactive effects of the key variables of interest with disease type/severity
were captured in the statistical analysis. To do this, a predicted probability of disease type and
severity (IPF and COPD stage 3) allowing for an interaction between the NFATc3 expression
and nuclear translocation indicators and disease was constructed. The intensity scores were
included separately to test for an independent effect on FEV/1FVC % and their impact nested
with disease type.

Results
VIP regulates NFATc3 activity
We have previously demonstrated that 2 days of CH exposure causes NFATc3 activation in
isolated intra pulmonary arteries in mice [6]. In the same study, we have shown that NFATc3
is the only isoform activated by CH and that its activation is associated with increased NFATc3
nuclear localization in PASMC [6]. Here, we show that CH-induced NFAT activation in isolated intra pulmonary arteries was abrogated by treating mice with VIP one day prior and during CH exposure (Fig 1A).
Furthermore, VIP (1 μM) attenuated ET-1 (100 nM)-induced NFATc3 nuclear translocation in cultured human PASMC (Fig 1B). Consistent with these findings, NFATc3 nuclear
localization was enhanced in PASMC from VIP KO compared to WT mice (Fig 2).
Taken together these results suggest that VIP is an endogenous inhibitor of NFATc3. These
findings provided the rationale for determining NFATc3 activity status in COPD and IPF
patients.

Airway and vascular remodeling in COPD and IPF patients
Grading of histology by a pathologist blinded to identities of the samples showed significant
airway remodeling in the IPF group (group 4) compared to the other three groups (Fig 3).
There was no significant difference in vascular remodeling among the four groups (Fig 3).

NFATc3 activity and expression in lungs from COPD and IPF patients–
Descriptive Outcomes
It is known that NFATc3 nuclear accumulation is a primary step in the NFATc3 activation
pathway. We focused on the NFATc3 isoform because it is activated in pulmonary arteries by

PLOS ONE | DOI:10.1371/journal.pone.0170606 January 26, 2017

5 / 18

NFATc3 and VIP in IPF and COPD

Fig 1. VIP attenuates NFAT activation. A) VIP administration inhibited CH-induced NFAT activation in isolated mouse
intrapulmonary arteries. RLU = relative luciferase units. N = normoxia, CH V = 2 days chronic hypoxia. CH VIP = VIP (0.166
mg/kg/day) in osmotic pump one day prior and during CH exposure for 2 days. *p<0.05 vs N and CH VIP, n = 3–5 mice.
ANOVA followed by Newman-Keuls. B) VIP attenuated ET-1-induced NFATc3-EGFP nuclear import in human PASMC.
*p<0.05, n = 5 cells. t-test.
doi:10.1371/journal.pone.0170606.g001
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Fig 2. PASMC NFATc3 nuclear accumulation is enhanced in VIP KO mice. Top: representative immunofluorescence confocal microscopy
images. Nuclei depicted in green (SYTOX), NFATc3 in red and α-actin in blue. NFATc3 nuclear co-localization in white (see white arrows).
Bottom: summary of percent of PASMC with NFATc3 in the nucleus. n = 15 to 28 arteries from 6 mice each group. *p<0.001
doi:10.1371/journal.pone.0170606.g002

CH [6,30] and also because VIP attenuates its activation (Fig 1). Here, the % of nuclei of
PASMC, pulmonary artery endothelial cells (PAEC), airway epithelial (AEPC) and smooth
muscle cells (ASMC) that were positive for NFATc3 in lung sections from the four groups of
patients was determined as a marker of NFATc3 activation. The average intensity of NFATc3
staining in the same cell types was measured to determine the differences in NFATc3 protein
expression among the groups. Furthermore, NFATc3 mRNA levels were assessed by real time
PCR in lungs from the four groups of patients. There was no significant difference in the % of
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Fig 3. Airway and vascular remodeling graphed based on severity of histology. Group 1 COPD FEV1<50%; Group 2 COPD FEV
50–80%; Group 3 COPD, control, FEV1>80%; Group 4 IPF FVC<50%. One-way analysis of variance (ANOVA) determined that means of
airway remodeling scores were significantly different (p<0.002), and Post hoc Tukey’s Multiple Comparison Test found that Group 4
compared to each of the other three groups was significant for differences in airway remodeling (p<0.05 for each comparison). n = 5–7
doi:10.1371/journal.pone.0170606.g003

NFATc3 positive nuclei or intensity among the different groups in any of the cell types analyzed (Figs 4 and 5).
Neither was there a significant difference in NFATc3 mRNA levels among the groups (Fig 6).
Table 1 summarizes means and frequencies of the variables used in our hypotheses tests by
disease type and severity.
The largest and statistically significant differences were between advanced COPD (group 3)
and IPF (group 4). In fact, as COPD progresses the FEV1/FVC % declined while in IPF
patients it remained high. Non-whites and males were disproportionately represented in the
severe COPD group. IPF patients were significantly younger than COPD patients. IPF patients
smoke significantly less than COPD patients. These results supported a multivariate analysis to
capture isolated effects of key independent variables.

NFATc3 activity and expression in lungs from COPD and IPF patients–
Multivariate Analysis
Table 2 reports the multivariate analysis results for predicting FEV1/FVC %.
In all models, the isolated impact of a high NFATc3 intensity in airway cells is positive on
the lung functioning score and that of the pulmonary vascular NFATc3 intensity score is not
statistically significant. The interesting finding reported in Table 3 is that among IPF patients
with high NFAT score (NFATc3 intensities and % positive nuclei), the FEV1/FVC % is
between 61% higher than among COPD patients. The score is 64% lower for COPD patients of
group 3 relative to the less severe COPD patients (Group 1). Models that do not allow for the
interaction between disease and NFATc3 indicators are noisier with poor model fit. This further re-enforced the differences in NFATc3 expression and nuclear translocation between IPF
and COPD patients.
After controlling for confounding factors VIP mRNA levels are an important predictor of
FEV1/FVC %. Those with high levels of VIP mRNA have significantly lower FEV1/FVC %.
This is also true for females. Descriptive analysis was not able to capture significant differences
in lung VIP mRNA levels among the groups of patients (Fig 6B). Multivariate analysis allows
identification of isolated effects removing the noise from the confounding factors.
Remodeling results. Given models with the interaction between NFATc3 indicators and
disease are the preferred specification for testing hypotheses of interest, we only report those
results in Table 3 for the remodeling outcome.
Airway remodeling findings. Little independent impact of any of the NFATc3 indicators
on airway remodeling was observed (the signs shift across the two models and are not significant). We do see a significant and negative impact of higher percent positive NFATc3 ASMC
nuclei scores on the airway remodeling score (by 8%). Because of collinearity with the interaction controls this effect goes away in Model 2 because it is picked up in the interacted indicators. The main differences of the impact of higher levels of NFATc3 on airway remodeling
scores work through disease with both IPF and severe COPD patients exhibiting lower remodeling outcomes relative to less severely ill COPD patients. IPF patients with high scores on the
NFATc3 indicators have airway-remodeling scores that are 2.71 points lower on average compared to groups 1 and 2 COPD patients. COPD3 patients have airway-remodeling scores that
are 4.39 percent lower than their less severe counterparts.
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Fig 4. NFATc3 activity and expression in pulmonary artery endothelial and smooth muscle cells from lungs from COPD and
IPF patients. A) Representative images of NFATc3 (red) and smooth muscle alpha-actin (blue) immunostaining of lung sections of
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patients from groups 1–4. Nuclei were stained with Sytox green. NFATc3 nuclear co-localization is shown in white. Scale bar = 50 μm.
B) Summary results of endothelial cell (EC) NFATc3 staining intensity, % NFATc3+ EC nuclei, vascular smooth muscle (VSMC)
NFATc3 staining intensity and % NFATc3+ VSMC nuclei. N = 7–14 patients. ANOVA followed by Newman-Keuls.
doi:10.1371/journal.pone.0170606.g004

Vascular remodeling results. Airway cell NFATc3 expression intensity has a significant
negative relationship with vascular remodeling and the effect appears to be independent of disease type for this outcome. Age and VIP mRNA levels proved to be important predictors as
well.

Discussion
Our study shows a novel link between the pro-inflammatory and pro-vascular remodeling
gene NFAT, the anti-inflammatory anti-vascular remodeling gene VIP, with the diseases
COPD and IPF.
IPF is a chronic fibrosing interstitial lung disease that is characterized by the histopathological pattern of usual interstitial pneumonia [31]. While the pathogenesis of IPF is largely
unknown, it is characterized by irreversible fibrosis and bronchiolar honeycombing, and
involves genetic abnormalities [32]. Accumulation of fibroblasts, myofibroblasts and extracellular matrix proteins leads to hypoxia within the lung [32]. Hypoxia causes fibroblast [33] and
pulmonary arterial smooth muscle proliferation [4] in an NFAT-dependent manner. On the
other hand, it has been shown that hypoxia decreases lung VIP levels in rats [34] and VIP can
cause relaxation and inhibition of vascular smooth muscle cell proliferation [26]. The property
of VIP to inhibit NFATc3 in mouse pulmonary artery smooth muscle both in vivo and in culture, and the finding that NFAT activity is enhanced in vivo in pulmonary artery smooth muscle from VIP KO mice, strongly supports the concept that VIP and NFAT are inextricably
intertwined. VIP appears to act as an endogenous inhibitor of NFAT activity, attenuating pulmonary hypertension. Our determination that NFAT activity in IPF patient lungs is associated
with higher FEV1/FVC ratio than that of COPD patients in the earlier stages of the disease suggests activation occurs early in the throes of IPF pathogenesis. NFATc3 expression and activity
negatively correlates with airway remodeling in IPF patients but no significant correlation was
observed with vascular remodeling. We further show that there is a significant positive correlation between NFATc3 mRNA expression and VIP mRNA expression only in lungs from IPF
patients. These results suggest that downstream consequences of lung fibrosis leading to hypoxia and pulmonary hypertension can conceivably be due to a dysregulation in the balance
between NFAT activity and VIP levels.
COPD frequently causes pulmonary hypertension because is a disease characterized by
chronic airflow limitation resulting and hypoxemia from an abnormal inflammatory response
to gas and particle inhalation, and is largely irreversible and progressive [35]. COPD involves
alveolar emphysematous dilation and bronchiolar inflammation with a predominance of
CD8+ T lymphocytes and neutrophils [36]. It has been recently shown that the number of
CD8+/NFATc2+ T cells is increases in the lungs of COPD patients compared to controls and
that NFAT inhibition with either cyclosporine or calcium-release activation calcium channels
inhibitor (syntax-66) produces greater anti-inflammatory effects on COPD CD8+ cells than
corticosteroids [37]. Furthermore, NFAT is up-regulated in peripheral blood mononuclear
cells of subjects with severe COPD [36]. Consistent a possible role of NFAT in the pathogenesis of the inflammation present in COPD, we have previously demonstrated that NFATc3 is
required for CH-induced pulmonary hypertension in mice [4,6]. Furthermore, silencing of
stromal interaction molecule 1 (STIM1), a Ca+2 sensor on the endoplasmic reticulum, attenuated hypoxia-induced increases in rat pulmonary artery smooth muscle cell proliferation by
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Fig 5. NFATc3 activity and expression in airway epithelial and smooth muscle cells from lungs from COPD and IPF
patients. A) Representative images of NFATc3 (red) and smooth muscle alpha-actin (blue) immunostaining of lung sections of
patients from groups 1–4. Nuclei were stained with Sytox green. NFATc3 nuclear co-localization is shown in white. Scale bar = 50
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μm. B) Summary results of airway epithelial cells (AEPC) NFATc3 staining intensity, % NFATc3+ AEPC nuclei, airway smooth
muscle (ASMC) NFATc3 staining intensity and % NFATc3+ ASMC nuclei. N = 5–7 patients. ANOVA followed by Newman-Keuls.
doi:10.1371/journal.pone.0170606.g005

Fig 6. NFATc3 and VIP mRNA levels in lungs from COPD and IPF patients. NFATc3 and VIP mRNA levels were determined by real time PCR
in lungs from patients from groups 1–4.
doi:10.1371/journal.pone.0170606.g006

Table 1. Means and Frequencies of FEV1/FVC % and Key Explanatory Variables By Disease State.
Variables

COPD Group 1 N = 14

COPD Group 2 N = 8

COPD Group 3 N = 7

IPF Group 4 N = 10

0.97**

0.67**

0.36**

1.03**

%NFATc3+ASMC nuclei1

4.70/10.96

6.12/9.80

19.37

2.88/4.79

%NFATc3+AEPC nuclei1

5.34/12.48

5.61/8.98

12.08

2.80/4.66

%NFATc3+ PASMC nuclei

7.33

12.62

18.11

9.79

%NFATc3+ PAEC nuclei

13.65

22.08

29.41

15.08

% NFATc3+ASMC nuclei

-0.23

0.13

0.48

-0.11

% NFATc3+ AEPC nuclei

-0.17

-0.04

0.71

-0.24

Lung VIP mRNA

1.59

3.21

1.86

1.3

Lung NFATc3 mRNA

1.81

1.87

2.43

2.4

PASMC NFATc3 Intensity

74.85**

78.65**

80.78**

80.53**

PAEC NFATc3 Intensity

87.53**

89.81**

90.74**

85.93**

ASMC NFATc3 Intensity

29.79**

26.10**

30.82**

26.24**

AEPC NFATc3 Intensity

27.25**

24.71**

26.65**

24.39**

% White

100**

100**

85.71**

90.00**

% Female

42.9

50

71.43

40

Age

71.43**

62.75**

54.43**

49.9**

Packs Smoked/year

29.43

24.63

29.71

6.8

Dependent Variables
FEV1/FVC %
Independent Variables

FEV1 (Forced Expiratory Volume 1), FVC (Forced Vital Capacity).1There was roughly a 40% missing value rate on the ASMC and AEPC indicators for all
but Group 3. We report the means with and without the missing. We coded the missing as 0 which is why including them yields a much lower mean.
**Significant at the 5% level.
doi:10.1371/journal.pone.0170606.t001
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Table 2. FEV1/FVC by Intensity of NFATc3 and RNA.
Variable

Model 1

Model 2

Model 3

Airway Cell NFATc3 Intensity
ASMC

0.02 (0.02)

AEPC

-0.04 (0.04)

0.02 (0.01)**

0.02 *0.01)**

0.01 (0.01)

0.01 (0.01)
-0.03 (0.01)**

Pulmonary Vascular NFATc3 Intensity
PASMC

0.05 (0.04)

-0.008 (0.01)

-0.02 (0.01)**

0.0004 (0.00)

0.01 (0.003)*

0.01 (0.01)

-0.01 (0.00)**

-0.01 (0.002)**

%NFATc3+ AEPC nuclei

-0.01 (0.01)

0.01 (0.00)*

0.01 (0.003)**

%NFATc3+ PASMC nuclei

-0.04 (0.03)

0.01 (0.01)

0.01 (0.01)

%NFATc3+ PAEC nuclei

0.02 (0.02)

0.004 (0.01)

0.01 (0.01)*

VIP mRNA

-0.13 (0.06)**

-0.07 (0.03)**

-0.08 (0.03)**

NFATc3 mRNA

-0.08 (0.05)*

0.01 (0.02)

0.03 (0.03)

NFAT Int !IPF

-

0.62 (0.14)**

0.61 (0.14)**
-0.64 (0.09)**

PAEC
%NFATc3+ ASMC nuclei

NFAT Int!COPD3

-

-0.64 (0.09)**

Packs per year

-0.02 (0.01)*

0.003 (0.004)

0.003 (0.004)

Female

-0.11 (0.20)

-0.21 (0.07)**

-0.20 (0.07)**

-0.007 (0.006)

0.005 (0.003)

0.004 (0.003)

0.5789

0.9684

0.9674

Age
R-Square

Model 1 does not include the impact of the NFATc3 intensities or the % positive nuclei indicators through the
patient’s disease type. Model 2 allows NFATc3 intensities to work through disease type. Model 3 allows the
NFATc3 intensities and % positive nuclei to interact with disease type.
**Significant at the 5% level. Standard Errors in (). n = 23.
doi:10.1371/journal.pone.0170606.t002

inhibiting NFATc3 nuclear import [38] further supporting a role for NFATc3 in CH-induced
pulmonary hypertension in rats. Contrary to our expectations, we found no significant differences in NFATc3 expression and/or activity among patients with different degrees of severity
Table 3. Remodeling Outcomes Using All Intensity Indicators Working Through Disease.
Variable
Airway Cell NFATc3 Intensity
Pulmonary Vascular NFATc3 Intensity

Airway 1

Airway 2

Vascular 1

Vascular 2

-0.45 (0.63)

0.81 (0.68)

-3.96 (3.01)

-2.57 (1.63)*

0.33 (0.36)

-0.41 (0.37)

1.34 (1.76)

0.88 (0.90)

-0.08 (0.02)**

-0.16 (0.06)

0.08 (0.1)

0.002 (0.15)

%NFATc3+ AEPC nuclei

0.06 (0.11)

-0.04 (0.16)

0.59 (0.5)

0.44 (0.38)

%NFATc3+ PASMC nuclei

-0.01 (0.11)

0.21 (0.15)

-0.59 (0.6)

-0.32 (0.37)

0.01 (0.03)

-0.01 (0.05)

0.06 (0.2)

0.01 (0.12)

0.46 (0.20)**

0.12 (0.26)

1.32 (0.98)

1.04 (0.63)*

%NFATc3+ ASMC nuclei

%NFATc3+ PAEC nuclei
VIP mRNA
NFATc3 mRNA

1.52 (0.30)**

0.98 (0.44)**

1.13 (1.44)

0.75 (1.06)

NFAT Int !IPF

-4.12 (1.10)**

-2.71 (1.14)**

-4.68 (5.3)

-3.10 (2.74)

NFAT Int!COPD3

-4.70 (0.5)**

-4.39 (1.07)**

-2.00 (2.6)

-2.24 (2.58)

0.04 (0.03)

-0.02 (0.04)

0.16 (0.14)

0.11 (0.09)

Female

1.86 (0.71)**

2.70 (1.19)**

-2.15 (3.5)

-0.95 (2.88)

Age

-0.10 (0.02)**

-0.03 (0.02)

-0.17 (0.11)

-0.11 (0.05)**

0.942

0.9841

0.2972

0.8841

Packs per year

R-Square

Airway and Vascular 1 Models allow NFAT intensities alone to interact with disease type. Airway and Vascular 2 Models allow both NFAT intensities and %
+ nuclei to interact with disease type.
**Significant at the 5% level. Standard Errors in (). n = 15
doi:10.1371/journal.pone.0170606.t003
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of COPD in any of the lung cells in which it was determined. When a multivariate analysis was
used, NFATc3 expression/activity scores were 64% lower for COPD patients of group 3 relative to the less severe COPD patients (Group 1) and VIP mRNA lung levels were higher in
those COPD patients with lower FEV/FVC ratios. These results suggest that VIP is upregulated
in the lung of severe COPD patients and might be inhibiting NFAT.
Since NFAT activity is higher in IPF with higher FEV1/FVC ratios compared to COPD
patients, indicating a late-phase disease state, it is plausible that treating smokers with VIP
would reduce the risk of being diagnosed with IPF and that treating early IPF with VIP may
inhibit progression of airway and vascular remodeling. In support of this possibility, VIP has
been successfully used to improve symptoms and function in COPD patients, supporting its
role in counteracting NFAT [39]
In conclusion, NFATc3 and VIP inextricably linked via a regulatory relationship in both
COPD and IPF, supporting the concept that pathogenesis is mediated by NFATc3 and VIP
may have a novel therapeutic role.
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S3 Table. Impact of NFATc3 Intensity and Percent Positive Nuclei on Disease. 1Rho represents the correlation in the error terms across the two equations. The significance suggests that
there is something unobserved that is common to both equations.
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